Cost-Cutting Boosting Pharma Earnings
Big pharmaceutical companies are getting lean in an attempt to boost profitability before they lose patent protection on several important drugs, says Morningstar's Damien Conover.
Jeremy Glaser: For Morningstar, I am Jeremy Glaser. We're half way through pharma earnings season, and I am here with associate director Damien Conover, see what we've learned so far and what we can expect in the other half of earnings.
Damien thanks for joining me today.
Jeremy Glaser does not own (actual or beneficial) shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.